Poliovirus Therapy for Recurrent Glioblastoma Has 3 Year Survival Rate of 21%

A new study reports a genetically modified poliovirus therapy has been shown to improve long term survival rates in recurrent glioblastoma brain cancer patients. Researchers say the therapy had a three year survival rate for 21 percent of participants in a phase 1 clinical trial, compared to just 4% of patients who received more standard treatments.